기업 정보 불러오는 중
Keep exploring
The themes Nexalin Technology is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plcUS$131.6BA+
SYKStryker Corp.US$117.9BA+
EWEdwards Lifesciences CorporationUS$61.6BA+
GEHCGE Healthcare Technologies Inc.US$37.5BA
GKOSGlaukos CorpUS$14.5BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026년 10월 21일CBGraded C, now B
MCKMckesson Corporation2026년 11월 4일BAGraded B, now A
CVSCVS Health Corp2026년 11월 4일BAGraded B, now A- EWEdwards Lifesciences Corporation2026년 11월 4일BAGraded B, now A
- GEHCGE Healthcare Technologies Inc.2026년 10월 28일CAGraded C, now A
어떻게 돈을 버는가
- Device sales45%
- Equipment and replacement parts30%
- Licensing fees16%
매출 비중은 year ended 2025-12-31 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.
경쟁 상대
- Fisher Wallace Laboratories
- Flow Neuroscience
무엇을 파는가5
Gen-1
An earlier cranial electrotherapy stimulation device used by medical professionals. Nexalin continues to service previously sold or leased devices but has paused new United States sales and marketing.
Gen-2 SYNC
A clinical-use device that delivers Nexalin’s newer 15-milliamp electrical waveform. It is under United States regulatory review and clinical development.
Gen-3 HALO
A headset being studied for physician-supervised treatment at home. A United States clinical trial for insomnia is underway.
2개 더 보기
Nexalin NeuroCare
Software for remote patient monitoring, doctors’ clinical workflows, collection of clinical data and virtual care.
Electrodes and patient cables
Replacement treatment components sold to medical providers using Nexalin devices.
누가 사는가2
- Medical professionals and clinics that use Nexalin devices with patients; licensing arrangements generally involve monthly fees, and some charge by the number of treatments.
- International distributors and customers that buy devices and related supplies; Nexalin recorded no international revenue in the six months ended 2026-06-30.
무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가
사업이 기대고 있는 것
- 1United States sales of new devices depend on Food and Drug Administration (FDA) clearance or approval; Nexalin’s HALO insomnia study and other clinical and regulatory work are part of that process.
- 2Device assembly, testing and quality checks rely mainly on third-party manufacturers.
- 3Clinical studies rely on outside research organizations and study sites to carry out trials and recruit participants.
- 4China distribution and future device registrations depend in part on Wider, which is responsible for pursuing approvals there.
잘못될 수 있는 일
- 1If clinical studies fail, take longer than planned or do not support regulatory applications, Nexalin may not obtain authorization to sell newer devices for the intended uses.
- 2Nexalin has limited revenue, recurring operating losses and negative operating cash flow; it says available funds are insufficient for at least twelve months from the financial statements’ issuance. Its ability to raise funds through its share-sale program is tied to continued Nasdaq listing, which was under review after a delisting determination.
- 3Nexalin depends on outside manufacturers and clinical research organizations. Delays, quality problems or failures to meet regulatory requirements could disrupt device production or clinical studies.
Nexalin Technology, Inc. 소개
Nexalin develops devices that use electrical signals delivered through electrodes on the head to stimulate the brain. Its SYNC device is intended for clinical use, while its HALO headset is being studied for physician-supervised home use; a clinical trial for insomnia is underway. Nexalin also develops software for doctors to oversee patients remotely, manage care and collect clinical information.
- 본사
- Houston, Texas
- 설립
- 2010
- 상장 시장
- Nasdaq Capital Market
- 회계연도 종료
- December 31
Nexalin Technology, Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.
